Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cutaneous arteritis combined with antiphospholipid syndrome associated with the use of immune checkpoint inhibitors in a patient with a metastatic lung adenocarcinoma.
Hayashi M, Shiraishi K, Yoshida S, Yatsuzuka K, Kohri N, Kuroo Y, Horie K, Muto J, Murakami M, Fujisawa Y. Hayashi M, et al. Among authors: fujisawa y. J Dermatol. 2024 May;51(5):e166-e167. doi: 10.1111/1346-8138.17063. Epub 2023 Dec 8. J Dermatol. 2024. PMID: 38063285 No abstract available.
Obituary: Thomas Fletcher Tedder, PhD (1956-2024).
Hasegawa M, Fujimoto M, Kadono T, Fujisawa Y, Kamata M, Matsushita T, Sato S. Hasegawa M, et al. Among authors: fujisawa y. J Dermatol Sci. 2024 Apr 23:S0923-1811(24)00068-9. doi: 10.1016/j.jdermsci.2024.04.003. Online ahead of print. J Dermatol Sci. 2024. PMID: 38719727 No abstract available.
Eribulin mesylate exerts antitumor effects via CD103.
Oya K, Nakamura Y, Watanabe R, Tanaka R, Ichimura Y, Kubota N, Matsumura Y, Tahara H, Okiyama N, Fujimoto M, Nomura T, Fujisawa Y. Oya K, et al. Among authors: fujisawa y. Oncoimmunology. 2023 May 27;12(1):2218782. doi: 10.1080/2162402X.2023.2218782. eCollection 2023. Oncoimmunology. 2023. PMID: 37261089 Free PMC article.
Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T, Yoshino K, Nakamura M, Kato H, Ito T, Maekawa T, Fujisawa Y, Matsushita S, Amagai R, Yamazaki E, Takahashi M, Tamabuchi E, Hashimoto A, Kambayashi Y, Yamazaki N, Miyata T, Asano Y. Fujimura T, et al. Among authors: fujisawa y. Exp Dermatol. 2024 Jan;33(1):e14976. doi: 10.1111/exd.14976. Epub 2023 Nov 9. Exp Dermatol. 2024. PMID: 37946551
858 results